Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai Fosun Pharmaceutical (Group) Co Cash-to-Debt?
Shanghai Fosun Pharmaceutical (Group) CoSFOSF 77 Cash-to-Debt is 0.39 as of Mar. 2026, which is 15% below its 10-year median of 0.46. GuruFocus rates SFOSF with a GF Score™ of 77/100 and a GF Value™ of $2.19 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 983 Drug Manufacturers companies, Shanghai Fosun Pharmaceutical (Group) Co ranks worse than 66.02% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shanghai Fosun Pharmaceutical (Group) Co's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.39.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Shanghai Fosun Pharmaceutical (Group) Cocouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Shanghai Fosun Pharmaceutical (Group) Co Cash-to-Debt Related Terms
Shanghai Fosun Pharmaceutical (Group) Co Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Shanghai Fosun Pharmaceutical (Group) Co Cash-to-Debt Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co Cash-to-Debt vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a Cash-to-Debt of 0.39 as of Mar. 2026. This is 15% below median its historical median of 0.46. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt has ranged from 0.35 to 0.70. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #649 out of 983 companies in the Drug Manufacturers industry, placing it in the top 66%.
Is Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Cash-to-Debt of 0.39 is 15% below median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.70. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Shanghai Fosun Pharmaceutical (Group) Co's value of 0.39 is 60.2% below this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #649 out of 983 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #649 out of 983 companies for Cash-to-Debt. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median Cash-to-Debt is 0.98. Shanghai Fosun Pharmaceutical (Group) Co's value of 0.39 is 60.2% below this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own Cash-to-Debt has ranged from 0.35 to 0.70 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.98, Shanghai Fosun Pharmaceutical (Group) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current Cash-to-Debt of 0.39 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current Cash-to-Debt is 0.39, which is 15% below median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.19, compared to a current price of $1.95 — trading 11% below its estimated fair value. The current Cash-to-Debt is 0.39, which is 15% below median its 10-year median of 0.46 and 60.2% below the Drug Manufacturers industry median of 0.98. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current Cash-to-Debt is 0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $1.95 is trading 11% below its estimated GF Value™ of $2.19.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SFOSF:
Cash-to-Debt: 0.39 (15% below median its 10-year median of 0.46)
GF Value™: $2.19 vs. price of $1.95 (11% below fair value)
Industry Position: 60.2% below the Drug Manufacturers median (#649 of 983)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
77GF Score
Get the complete analysis for SFOSF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
